| 产品描述: | AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer. |
| 靶点: |
IC50: 0.6 nM (ER binding); 0.4 nM (ER degradation) |
| 体外研究: |
AZ'6421 (example 72) exhibits anti-tumour activity via the ability to degrade the estrogen receptor in a number of different breast cancer cell-lines (MCF-7, CAMA-I, and BT474). AZ'6421 (0.3 μM) has ER binding and ER degradation with IC50 values of 0.6 nM and 0.4 nM, respectively in MCF-7 cell lines. |
| 参考文献: |
1. Bin Yang, et al. Compounds and their use in treating cancer. Patent WO2019123367A1. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.025 ml |
5.127 ml |
10.255 ml |
| 5 mM |
0.205 ml |
1.025 ml |
2.051 ml |
| 10 mM |
0.103 ml |
0.513 ml |
1.025 ml |
| 50 mM |
0.021 ml |
0.103 ml |
0.205 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |